JP2024508755A5 - - Google Patents

Info

Publication number
JP2024508755A5
JP2024508755A5 JP2023549605A JP2023549605A JP2024508755A5 JP 2024508755 A5 JP2024508755 A5 JP 2024508755A5 JP 2023549605 A JP2023549605 A JP 2023549605A JP 2023549605 A JP2023549605 A JP 2023549605A JP 2024508755 A5 JP2024508755 A5 JP 2024508755A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
unsubstituted
compound according
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508755A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016487 external-priority patent/WO2022177917A2/en
Publication of JP2024508755A publication Critical patent/JP2024508755A/ja
Publication of JP2024508755A5 publication Critical patent/JP2024508755A5/ja
Pending legal-status Critical Current

Links

JP2023549605A 2021-02-16 2022-02-15 Krasを阻害するための組成物及び方法 Pending JP2024508755A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163150011P 2021-02-16 2021-02-16
US63/150,011 2021-02-16
US202163246181P 2021-09-20 2021-09-20
US63/246,181 2021-09-20
PCT/US2022/016487 WO2022177917A2 (en) 2021-02-16 2022-02-15 Compositions and methods for inhibition of ras

Publications (2)

Publication Number Publication Date
JP2024508755A JP2024508755A (ja) 2024-02-28
JP2024508755A5 true JP2024508755A5 (https=) 2025-03-13

Family

ID=80685119

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549605A Pending JP2024508755A (ja) 2021-02-16 2022-02-15 Krasを阻害するための組成物及び方法

Country Status (11)

Country Link
US (1) US20240246954A1 (https=)
EP (1) EP4294799A2 (https=)
JP (1) JP2024508755A (https=)
KR (1) KR20240002245A (https=)
AU (1) AU2022224511A1 (https=)
BR (1) BR112023016299A2 (https=)
CA (1) CA3209083A1 (https=)
IL (1) IL304986A (https=)
MX (1) MX2023008463A (https=)
TW (1) TW202245779A (https=)
WO (1) WO2022177917A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
CA3191279A1 (en) 2020-08-28 2022-03-03 Yi Liu Heterocyclic compounds and uses thereof
MX2023010430A (es) * 2021-03-12 2023-09-12 Bristol Myers Squibb Co Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
MX2023012725A (es) * 2021-04-29 2024-09-23 Amgen Inc Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos.
US20250059205A1 (en) * 2021-04-29 2025-02-20 Amgen Inc. Heterocyclic Compounds and Methods of Use
WO2022261154A1 (en) * 2021-06-09 2022-12-15 Eli Lilly And Company Substituted fused azines as kras g12d inhibitors
IL310291A (en) * 2021-07-23 2024-03-01 Theras Inc Compositions and methods for inhibition of ras
US20240409558A1 (en) * 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
WO2023072188A1 (zh) * 2021-10-29 2023-05-04 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
CN116253748A (zh) * 2021-12-09 2023-06-13 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为kras g12d抑制剂
WO2023114733A1 (en) * 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
AR128212A1 (es) * 2022-01-06 2024-04-10 Theras Inc Composiciones y métodos para la inhibición de ras
AR128211A1 (es) * 2022-01-06 2024-04-10 Theras Inc Composiciones y métodos para la inhibición de ras
CN118556063A (zh) * 2022-01-21 2024-08-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
EP4371991A4 (en) 2022-01-21 2025-02-26 Usynova Pharmaceuticals Ltd. Benzopyrimidine compounds and use thereof
AU2023216698A1 (en) * 2022-02-03 2024-06-13 Mirati Therapeutics, Inc. Quinazoline pan-kras inhibitors
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
MX2024010045A (es) * 2022-02-16 2024-08-26 Amgen Inc Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas mutantes kras.
EP4479398A1 (en) * 2022-02-16 2024-12-25 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
AU2023231139A1 (en) 2022-03-11 2024-09-05 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
JP2025510656A (ja) * 2022-03-24 2025-04-15 ベイジーン スウィッツァーランド ゲーエムベーハー 複素環式化合物、その組成物、及びそれらを用いた治療方法
CN116891488B (zh) * 2022-04-11 2025-12-12 成都海博为药业有限公司 稠环化合物、包含其的药物组合物及应用
WO2023225252A1 (en) * 2022-05-20 2023-11-23 Theras, Inc. Compositions and methods for inhibition of ras
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
WO2023246777A1 (en) * 2022-06-20 2023-12-28 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024008179A1 (en) * 2022-07-07 2024-01-11 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
IL318647A (en) 2022-08-05 2025-03-01 Kumquat Biosciences Inc Heterocyclic compounds and their uses
US20260035376A1 (en) 2022-08-05 2026-02-05 Theras, Inc. Compositions and methods for inhibition of ras
US20260042764A1 (en) * 2022-08-05 2026-02-12 Theras, Inc. Compositions and methods for inhibition of kras
US20260083750A1 (en) * 2022-08-26 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2024063576A1 (ko) * 2022-09-23 2024-03-28 일동제약(주) Kras 저해 물질로서 신규한 퀴나졸린 화합물
CN120077051A (zh) * 2022-10-21 2025-05-30 苏州亚盛药业有限公司 Kras抑制剂
AU2023382606A1 (en) * 2022-11-14 2025-05-08 Amgen Inc. Macrocyclic kras inhibitors and methods of use
CN116554208A (zh) * 2022-12-02 2023-08-08 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为kras g12d抑制剂
CN116082115A (zh) * 2023-01-06 2023-05-09 河南省科学院化学研究所有限公司 一种2-溴-4-氯-9,9’-二甲基芴的合成方法
KR20260041941A (ko) 2023-03-15 2026-03-27 콴타 테라퓨틱스, 인크. Kras 조절 인자 및 이의 용도
KR20250164300A (ko) * 2023-03-30 2025-11-24 일라이 릴리 앤드 캄파니 KRas 억제제
WO2024243025A1 (en) * 2023-05-19 2024-11-28 Ikena Oncology, Inc. Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions
CN121464141A (zh) * 2023-06-29 2026-02-03 海思科医药集团股份有限公司 一种5元杂芳基衍生物及其在医药上的应用
WO2025019823A1 (en) * 2023-07-20 2025-01-23 Merck Sharp & Dohme Llc Small molecule protein degraders of kras g12d mutant
WO2025049402A1 (en) * 2023-08-28 2025-03-06 Quanta Therapeutics, Inc. Kras modulators and uses thereof
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024337016A1 (en) * 2023-09-08 2026-04-16 Tyligand Bioscience (Shanghai) Limited Ras inhibitor
CN121969634A (zh) * 2023-10-08 2026-05-01 成都海博为药业有限公司 一种稠环化合物及应用
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025090811A1 (en) * 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Methods of modulating cell proliferation
WO2025117828A1 (en) * 2023-12-01 2025-06-05 Theras, Inc. Compositions and methods for inhibition of ras

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016049568A1 (en) * 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
US9988357B2 (en) * 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
PE20260440A1 (es) * 2018-11-09 2026-02-19 Hoffmann La Roche Compuestos de anillo fusionado
CN112110918B (zh) * 2019-06-21 2023-08-22 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物,其制法与医药上的用途
EP4065231A1 (en) * 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022002102A1 (en) * 2020-06-30 2022-01-06 InventisBio Co., Ltd. Quinazoline compounds, preparation methods and uses thereof
CN113880827B (zh) * 2020-07-03 2024-10-01 苏州闻天医药科技有限公司 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
WO2022068921A1 (zh) * 2020-09-30 2022-04-07 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用

Similar Documents

Publication Publication Date Title
JP2024508755A5 (https=)
JP2024501641A5 (https=)
JP2024516633A5 (https=)
IL304986A (en) Compositions and methods for inhibition of ras
JP2019518050A5 (https=)
JP2006504766A5 (https=)
JP2023500611A5 (https=)
RU2472509C2 (ru) Способ лечения артрита
JP2014500295A5 (https=)
JP2001526269A5 (https=)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2020533352A5 (https=)
JP2020534263A5 (https=)
JP2009073834A (ja) Hdac阻害剤による癌処置法
JP2020532547A5 (https=)
JP2022501370A5 (https=)
JP2005538099A5 (https=)
JP2023533485A5 (https=)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
JP2019526546A5 (https=)
JP2023550591A5 (https=)
HUP0203121A2 (hu) Szubsztituált benzimidazolokat tartalmazó gyógyszerkészítmény és alkalmazása
CN1283248C (zh) 包含埃坡霉素的组合及其药学应用
RU2008143556A (ru) Производные тиазолилдигидроиндазола в качестве ингибиторов протеинкиназ
WO2021201201A1 (ja) 新型コロナウイルス感染症(covid-19)の予防または治療剤および医薬組成物